SAB Biotherapeutics SABS
NASDAQ SABS
$3.06 -0.11 (-3.47%)
At close: Oct 1, 2026 · 4:00 PM EDT

SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026)

Updated

SAB Biotherapeutics (SABS) posted Depreciation & Amortization (CF) of $800,000 for Q2 2026, unchanged from $800,000 a year earlier and up 9.4% from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Depreciation & Amortization (CF) at SAB Biotherapeutics was $2.93 million, down 10.2% year-over-year; for FY2025, it was $3 million, down 36.2% from FY2024.

  • Annual Depreciation & Amortization (CF) shows a five-year compound annual growth rate of 50.9% (FY2020 to FY2025).
  • In prior years, SAB Biotherapeutics' Depreciation & Amortization (CF) was $4.71 million in FY2024 (+27.2%), $3.7 million in FY2023 (+15.6%), $3.2 million in FY2022 (+115.0%) and $1.49 million in FY2021 (+288.5%).
  • Quarterly Depreciation & Amortization (CF) has run from a low of $369,366 in Q3 2021 to a high of $2 million in Q1 2024 over five years.
  • The strongest year-over-year quarter for Depreciation & Amortization (CF) in the past five years was Q2 2022, with growth of 189.7%; the weakest was Q1 2025, with a decline of 60.0%.
  • According to Business Quant data, Depreciation & Amortization (CF) for the three prior quarters was $730,965 (Q1 2026), $700,000 (Q4 2025) and $700,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 SAB Biotherapeutics 264.67 Mn 264.67 Mn - 800,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 800,000.00
Mar 31, 2026 730,965.00
Dec 31, 2025 700,000.00
Sep 30, 2025 700,000.00
Jun 30, 2025 800,000.00
Mar 31, 2025 800,000.00
Dec 31, 2024 764,007.00
Sep 30, 2024 900,000.00
Jun 30, 2024 1.00 Mn
Mar 31, 2024 2.00 Mn
Dec 31, 2023 969,340.00
Sep 30, 2023 1.00 Mn
Jun 30, 2023 900,000.00
Mar 31, 2023 898,453.00
Dec 31, 2022 929,379.00
Sep 30, 2022 890,000.00
Jun 30, 2022 750,000.00
Mar 31, 2022 636,235.00
Dec 31, 2021 619,984.00
Sep 30, 2021 369,366.00
API Access

SAB Biotherapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=SABS&period=max&api_key=YOUR_API_KEY